Immuron Limited (AU:IMC) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immuron Limited, an Australian biopharmaceutical company, will feature CEO Steven Lydeamore presenting at the Peak Biotech Showcase in Melbourne. The company specializes in oral immunotherapies such as Travelan®, which aims to prevent travelers’ diarrhea. Immuron is also advancing IMM-529, a treatment for Clostridioides difficile infection, showing promise in pre-clinical trials.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.